106 related articles for article (PubMed ID: 31332656)
1. Long-Term Efficacy and Safety of Immunomodulatory Therapy for Atherosclerosis.
Thota LN; Ponnusamy T; Lu X; Mundkur L
Cardiovasc Drugs Ther; 2019 Aug; 33(4):385-398. PubMed ID: 31332656
[TBL] [Abstract][Full Text] [Related]
2. Immune regulation by oral tolerance induces alternate activation of macrophages and reduces markers of plaque destabilization in Apob
Thota LN; Ponnusamy T; Philip S; Lu X; Mundkur L
Sci Rep; 2017 Jun; 7(1):3997. PubMed ID: 28638138
[TBL] [Abstract][Full Text] [Related]
3. Regulating Inflammatory Immune Response to Atherogenic Antigens Prevents Development and Progression of Atherosclerosis in New Zealand White Rabbits.
Philip S; Ponnusamy T; Rao LN; Biradar S; Kumar R; Deshpande V; Lu X; Kakkar VV; Mundkur LA
Can J Cardiol; 2016 Aug; 32(8):1008.e1-1008.e10. PubMed ID: 27062234
[TBL] [Abstract][Full Text] [Related]
4. Impact of multiple antigenic epitopes from ApoB100, hHSP60 and Chlamydophila pneumoniae on atherosclerotic lesion development in Apob(tm2Sgy)Ldlr(tm1Her)J mice.
Lu X; Xia M; Endresz V; Faludi I; Szabo A; Gonczol E; Mundkur L; Chen D; Kakkar V
Atherosclerosis; 2012 Nov; 225(1):56-68. PubMed ID: 22959702
[TBL] [Abstract][Full Text] [Related]
5. Oral dosing with multi-antigenic construct induces atheroprotective immune tolerance to individual peptides in mice.
Mundkur L; Ponnusamy T; Philip S; Rao LN; Biradar S; Deshpande V; Kumar R; Lu X; Kakkar VV
Int J Cardiol; 2014 Aug; 175(2):340-51. PubMed ID: 24962340
[TBL] [Abstract][Full Text] [Related]
6. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis.
van Puijvelde GH; van Es T; van Wanrooij EJ; Habets KL; de Vos P; van der Zee R; van Eden W; van Berkel TJ; Kuiper J
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2677-83. PubMed ID: 17901374
[TBL] [Abstract][Full Text] [Related]
7. Effects of oral and subcutaneous administration of HSP60 on myeloid-derived suppressor cells and atherosclerosis in ApoE-/- mice.
Hu Y; Chen Z; Jiang L; Chen F; Jin R; Cheng L
Biochem Biophys Res Commun; 2018 Apr; 498(4):701-706. PubMed ID: 29107690
[TBL] [Abstract][Full Text] [Related]
8. Mucosal tolerance to a combination of ApoB and HSP60 peptides controls plaque progression and stabilizes vulnerable plaque in Apob(tm2Sgy)Ldlr(tm1Her)/J mice.
Mundkur L; Mukhopadhyay R; Samson S; Varma M; Kale D; Chen D; Shivaprasad S; Sivanandan H; Soman V; Lu X; Kakkar VV
PLoS One; 2013; 8(3):e58364. PubMed ID: 23505495
[TBL] [Abstract][Full Text] [Related]
9. Intranasal immunization with an apolipoprotein B-100 fusion protein induces antigen-specific regulatory T cells and reduces atherosclerosis.
Klingenberg R; Lebens M; Hermansson A; Fredrikson GN; Strodthoff D; Rudling M; Ketelhuth DF; Gerdes N; Holmgren J; Nilsson J; Hansson GK
Arterioscler Thromb Vasc Biol; 2010 May; 30(5):946-52. PubMed ID: 20167655
[TBL] [Abstract][Full Text] [Related]
10. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice.
Schiopu A; Frendéus B; Jansson B; Söderberg I; Ljungcrantz I; Araya Z; Shah PK; Carlsson R; Nilsson J; Fredrikson GN
J Am Coll Cardiol; 2007 Dec; 50(24):2313-8. PubMed ID: 18068040
[TBL] [Abstract][Full Text] [Related]
11. Identification of apoB-100 Peptide-Specific CD8+ T Cells in Atherosclerosis.
Dimayuga PC; Zhao X; Yano J; Lio WM; Zhou J; Mihailovic PM; Cercek B; Shah PK; Chyu KY
J Am Heart Assoc; 2017 Jul; 6(7):. PubMed ID: 28711866
[TBL] [Abstract][Full Text] [Related]
12. Effects of atorvastatin and diet interventions on atherosclerotic plaque inflammation and [
Hellberg S; Sippola S; Liljenbäck H; Virta J; Silvola JMU; Ståhle M; Savisto N; Metso J; Jauhiainen M; Saukko P; Ylä-Herttuala S; Nuutila P; Knuuti J; Roivainen A; Saraste A
Atherosclerosis; 2017 Aug; 263():369-376. PubMed ID: 28457625
[TBL] [Abstract][Full Text] [Related]
13. Immunization with a combination of ApoB and HSP60 epitopes significantly reduces early atherosclerotic lesion in Apobtm2SgyLdlrtm1Her/J mice.
Lu X; Chen D; Endresz V; Xia M; Faludi I; Burian K; Szabo A; Csanadi A; Miczak A; Gonczol E; Kakkar V
Atherosclerosis; 2010 Oct; 212(2):472-80. PubMed ID: 20609438
[TBL] [Abstract][Full Text] [Related]
14. Hypercholesterolemia Induced Immune Response and Inflammation on Progression of Atherosclerosis in Apob(tm2Sgy) Ldlr(tm1Her)/J Mice.
Rao LN; Ponnusamy T; Philip S; Mukhopadhyay R; Kakkar VV; Mundkur L
Lipids; 2015 Aug; 50(8):785-97. PubMed ID: 26178198
[TBL] [Abstract][Full Text] [Related]
15. ApoB-100 and HSP60 peptides exert a synergetic role in inhibiting early atherosclerosis in immunized ApoE-null mice.
Li J; Zhao X; Zhang S; Wang S; Du P; Qi G
Protein Pept Lett; 2011 Jul; 18(7):733-40. PubMed ID: 21413922
[TBL] [Abstract][Full Text] [Related]
16. Oral Tolerization with Mycobacterial Heat Shock Protein 65 Reduces Chronic Experimental Atherosclerosis in Aged Mice.
Wick C; Onestingel E; Demetz E; Dietrich H; Wick G
Gerontology; 2018; 64(1):36-48. PubMed ID: 28910785
[TBL] [Abstract][Full Text] [Related]
17. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques.
Silvola JM; Saraste A; Laitinen I; Savisto N; Laine VJ; Heinonen SE; Ylä-Herttuala S; Saukko P; Nuutila P; Roivainen A; Knuuti J
JACC Cardiovasc Imaging; 2011 Dec; 4(12):1294-301. PubMed ID: 22172786
[TBL] [Abstract][Full Text] [Related]
18. Oral administration of recombinant Mycobacterium smegmatis expressing a tripeptide construct derived from endogenous and microbial antigens prevents atherosclerosis in ApoE(-/-) mice.
Deshpande V; Krishnan R; Philip S; Faludi I; Ponnusamy T; Thota LN; Endresz V; Lu X; Kakkar VV; Mundkur LA
Cardiovasc Ther; 2016 Oct; 34(5):314-24. PubMed ID: 27241889
[TBL] [Abstract][Full Text] [Related]
19. Nuclear factor E2-related factor 2 deficiency impairs atherosclerotic lesion development but promotes features of plaque instability in hypercholesterolaemic mice.
Ruotsalainen AK; Lappalainen JP; Heiskanen E; Merentie M; Sihvola V; Näpänkangas J; Lottonen-Raikaslehto L; Kansanen E; Adinolfi S; Kaarniranta K; Ylä-Herttuala S; Jauhiainen M; Pirinen E; Levonen AL
Cardiovasc Res; 2019 Jan; 115(1):243-254. PubMed ID: 29917052
[TBL] [Abstract][Full Text] [Related]
20. Mucosal Administration of Collagen V Ameliorates the Atherosclerotic Plaque Burden by Inducing Interleukin 35-dependent Tolerance.
Park AC; Huang G; Jankowska-Gan E; Massoudi D; Kernien JF; Vignali DA; Sullivan JA; Wilkes DS; Burlingham WJ; Greenspan DS
J Biol Chem; 2016 Feb; 291(7):3359-70. PubMed ID: 26721885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
